Ignite Creation Date:
2024-05-06 @ 6:56 PM
Last Modification Date:
2024-10-26 @ 2:57 PM
Study NCT ID:
NCT05838664
Status:
COMPLETED
Last Update Posted:
2024-05-17
First Post:
2023-03-28
Brief Title:
A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation AF Between 2016 and 2020 in France
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
SIFNOS STUDY RETROSPECTIVE STUDY IN PATIENTS WITH ATRIAL FIBRILLATION AF EXPOSED AND UNEXPOSED TO AN ORAL ANTICOAGULANT THERAPY BETWEEN 2014-2020 IN FRANCE
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SIFNOS
Brief Summary:
The purpose of this study is to look at how many patients with AF had strokes major bleeding and death in both people who had and had not taken any oral anticoagulant Atrial fibrillation AF is an irregular and often very rapid heart rhythm arrhythmia that can lead to blood clots in the heart
This increases the risk of stroke Anticoagulants are medicines also called blood thinners which help prevent blood clots from forming or getting bigger
This study includes patients data from the database who
Had at least one hospital stay with AF
Are new users of OACs for AF treatment
Are 18 years and older when they were confirmed to have AF All the patients data included in this study would have either received the OAC therapy or not
This study aims to look at any events of strokes major bleeding and death The data of patients will be collected from the French national health insurance claims database SNDS The planned study period is thought to be from 1st January 2016 till 31st December 2020
This increases the risk of stroke Anticoagulants are medicines also called blood thinners which help prevent blood clots from forming or getting bigger
This study includes patients data from the database who
Had at least one hospital stay with AF
Are new users of OACs for AF treatment
Are 18 years and older when they were confirmed to have AF All the patients data included in this study would have either received the OAC therapy or not
This study aims to look at any events of strokes major bleeding and death The data of patients will be collected from the French national health insurance claims database SNDS The planned study period is thought to be from 1st January 2016 till 31st December 2020
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SIFNOS | OTHER | Alias Study Number | None |